.
MergerLinks Header Logo

Announced

Valo Health terminated the $2.8bn deal to go public via a SPAC merger with Khosla Ventures Acquisition.

Financials

Edit Data
Transaction Value£1,978m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Majority

Domestic

Private Equity

Merger

Reverse Takeover

De-SPAC

Single Bidder

Private

Friendly

Biotechnology

biotechnology

United States

Acquisition

Failed

Synopsis

Edit

Valo Health, a biotechnology company, terminated the $2.8bn deal to go public via a SPAC merger with Khosla Ventures Acquisition, a special purposes acquisition company. "We formed KVSA to merge with companies that are impactful to the world as we recently did with KVSB when we merged with Nextdoor. Valo Health is a strong company and we wish them continued success as they move forward on a very solid plan. We will continue to look for other high-impact targets across a range of industries to deliver maximum shareholder value," Samir Kaul, Khosla Ventures Founding Partner and Managing Director.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US